Skip to main content

Diabetes

  • J.D. Power and Associates: Roche Diabetes's Accu-Chek products scored highest in satisfaction in survey

    INDIANAPOLIS — Adults living with diabetes in the United States reported highest satisfaction using Roche Diabetes Care's Accu-Chek products compared with other blood-glucose-meter manufacturers, according to the inaugural J.D. Power and Associates 2012 Blood Glucose Meter Satisfaction Study released Tuesday. 

    The study gathered responses from 2,681 current meter users with type 1 and 2 diabetes in the U.S. to determine customer satisfaction across six factors: performance; ease of use; design; features; cost of test strips; and training.

  • Nebraska medication-management research study gets NACDS Foundation grant

    ARLINGTON, Va. — A university research project to look at the potential effects on patient health of incorporating medication management strategies into existing care teams has won a grant from the National Association of Chain Drug Stores' philanthropic arm.

    The NACDS Foundation said it gave the University of Nebraska Medical Center one of three research grants for the project, which will look at the effects of the strategies when they're incorporated into teams such as medical homes and accountable care organizations.

  • Pharmacists can improve health outcomes

    A new study conducted by researchers at the University of Minnesota and nearby healthcare institutions shows that patients with diabetes experience better outcomes when they undergo face-to-face medication therapy management sessions with pharmacists.

  • MTM improves outcomes in diabetes patients, study finds

    ARLINGTON, Va. — Face-to-face medication therapy management services can improve health outcomes for patients with diabetes, according to a new study.

  • Supplement may reduce gestational diabetes risk in some women, study finds

    NEW YORK — A nutritional supplement may help ward off gestational diabetes in pregnant women, according to a new study.

    The study, conducted by researchers at Italy's University of Messina and published in the journal Diabetes Care, found that pregnant women with family histories of Type 2 diabetes who received myo-inositol saw a significant reduction in the incidence of gestational diabetes, a condition that causes high blood sugar in some pregnant women.

  • FDA approves three new drugs for Type 2 diabetes

    SILVER SPRING, Md. — The Food and Drug Administration has approved three new drugs for Type 2 diabetes made by Takeda, the agency said Friday.

    The FDA announced the approval of Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone) tablets.

    Alogliptin is a new active ingredient, while metformin and pioglitazone are drugs already on the market.

  • J&J introduces innovation to diabetes diagnostics and insulin delivery space

    NEW YORK — During its annual business review Tuesday, Johnson & Johnson announced that the recent introduction of the OneTouch Verio Glucose testing platform represented one of the first diabetes care devices to alert and display high/low patterns that deliver more meaningful and actionable insights to help patients better understand and manage their diabetes.

  • FDA panel recommends approval for J&J Type 2 diabetes drug

    RARITAN, N.J. -- A panel of Food and Drug Administration experts has recommended approval for an experimental Type 2 diabetes drug made by Johnson & Johnson, the drug maker said.

    J&J said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had recommended approval for canagliflozin, which the company plans to market under the name brand Invokana. The FDA is not required to follow the votes of advisory committees when deciding whether or not to approve a drug, but usually does.

X
This ad will auto-close in 10 seconds